Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Personalis ( (PSNL) ) has issued an update.
On August 19, 2025, Personalis, Inc. announced a new task order under its contract with the U.S. Department of Veterans Affairs for the Million Veteran Program, effective September 30, 2025, valued at up to $13.5 million. This order increases the cumulative value of task orders received by Personalis under its contracts with the VA MVP to approximately $225.0 million, highlighting the company’s significant role in this large-scale genomic research initiative.
The most recent analyst rating on (PSNL) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Personalis stock, see the PSNL Stock Forecast page.
Spark’s Take on PSNL Stock
According to Spark, TipRanks’ AI Analyst, PSNL is a Neutral.
Personalis’ overall stock score is primarily impacted by its financial challenges, including declining revenues and negative profitability. Technical indicators suggest a bearish trend, and valuation metrics are unfavorable. However, strategic partnerships and potential growth in the MRD market provide some optimism for future performance.
To see Spark’s full report on PSNL stock, click here.
More about Personalis
Personalis, Inc. operates in the biotechnology industry, specializing in genomic sequencing and analytics services. The company focuses on providing advanced genomic solutions for research and clinical applications, including collaborations with government programs like the U.S. Department of Veterans Affairs’ Million Veteran Program.
Average Trading Volume: 1,241,791
Technical Sentiment Signal: Sell
Current Market Cap: $401.7M
See more data about PSNL stock on TipRanks’ Stock Analysis page.